Approximately 300 genes contribute to the ADME of xenobiotics, including the majority of drugs (http://pharmaadme.org/). Interindividual variability in expression and function of ADME genes are known to affect the individual response of patients to drugs with respect to therapeutic efficacy as well as adverse drug reactions (ADR). The heterogeneity in expression and function of ADME genes among individuals is determined by the interaction of genetic and nongenetic factors, as well as epigenetic modifications. 1 The influence of genetic variation in ADME genes and of nongenetic host factors, e.g., sex, age, disease state, or drug exposure, on drug response is the concept of personalized medicine. Meanwhile, major efforts are spent on implementing the pharmacogenomic (PGx) knowledge into clinical practice (http://www.fda.gov/drugs/ scienceresearch/researchareas/pharmacogenetics/ucm083378.htm; https://www.pharmgkb.org/page/cpic). PGx information is also part of labels of drugs used in various medical disciplines. Of note, about 70% of PGx information for drugs approved by the European Medicines Agency (EMA) between 1995 and 2014 is related to ADME processes. 2 In contrast, the significance of epigenetic regulation of gene expression in the context of drug response and ADME is just evolving and currently not part of drug labels.
The term "epigenetics" in general refers to heritable changes of gene expression without underlying changes in the encoding DNA sequence. 3 Epigenetic modifications regulating gene expression include DNA methylation, histone modification, and noncoding RNAs (miRNAs). 4 The interaction of these mechanisms forms a complex network and determines developmental or differentiation stage-specific expression patterns. In addition, the interplay of epigenetic modifications contributes to the regulation of tissue-and cell type-specific gene expression. Epigenetic modifications are dynamic and may change over time or in response to stimuli. [3] [4] [5] They are influenced by patient characteristics (e.g., gender, ethnicity), environment, lifestyle, and disease state or concomitant medication and contribute to individual phenotypes. Pharmacoepigenetics, in particular, address the epigenetic basis of interindividual variability of ADME genes, thereby contributing to the elucidation of unknown reasons for interindividual variability in drug response. Furthermore, epigenetic regulation of ADME genes can affect endogenous metabolism and deregulation can lead to the pathogenesis of various diseases. Recently, over 60 ADME genes have been considered to be influenced by histone modifications, DNA methylation, or miRNAs 6, 7 and evidence for an epigenetic component for the regulation of ADME gene expression has been rising ever since. Best evidence does exist for findings related to in vitro experiments using cell lines treated with the DNA methyltransferase (DNMT) inhibitor 5-aza-2 0 -deoxycytidine or the histone deacetylase (HDAC) inhibitor trichostatin A. Moreover, these findings are supported and/or supplemented by data from cancer tissues, where epigenetic deregulation of gene expression is a common phenomenon. 8 However, the clinical relevance of epigenetic regulation by DNA methylation on ADME gene expression and implications for drug safety and efficacy is so far limited. This review provides a summary and update of the currently available knowledge of the impact of DNA methylation on ADME genes, with particular focus on consequences for drug response.
DNA METHYLATION
One of the three major epigenetic mechanisms for the regulation of gene expression is DNA methylation. DNA methylation is a stable, covalent addition of a methyl (CH 3 ) group, occurring at 5 0 Cs of cytosines primarily within CpG dinucleotides (5-mC).
The modification is catalyzed either by de novo DNA methyltransferases (DNMT3a and DNMT3b) during development or by maintenance DNA methyltransferases (DNMT1) during DNA replication. In general, DNA methylation in promoter regions of genes suppresses their expression by directly inhibiting the binding of transcription factors or indirectly by recruiting methyl-CpG-binding proteins, which in turn modulate chromatin structure ( Figure 1 ). 4 DNA methylation marks are heritable and can be transmitted transgenerationally. 9 Despite heritability and stability, DNA methylation represents a dynamic process which changes throughout the course of a lifetime and in response to environmental stimuli and therefore contributes to phenotypic variation in humans. This phenomenon is best corroborated by studies examining genetically identical monozygotic twins, which show similar epigenetic marks during younger ages compared to older age, when remarkable epigenetic differences can be observed. 10, 11 Aberrant DNA methylation is associated with the pathogenesis and treatment response of cancer and various other diseases, e.g., psychiatric or autoimmune diseases, 8 and also affects expression of ADME genes. With respect to drug response, the dynamic nature of DNA methylation represents a major challenge. Thus, age dependency of DNA methylation and subsequent alteration of ADME gene expression need to be taken into consideration, especially in subpopulations such as children and the elderly. At the beginning of life and even in preterm infants there is convincing evidence that expression and function of drug metabolizing enzymes (DME) are significantly reduced compared to adults. For instance, CYP3A4 protein levels increase very gradually during the first year of life, and even 5-15-year-old children show significantly lower CYP3A4 levels compared with adults.
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Related to drug transporters, a similar picture can be assumed. 13, 14 Independent from other factors, there is first evidence that differences in DNA methylation patterns may contribute to the ontogeny of the expression of DME in childhood. 15 A higher risk for ADRs is well established in older patients, which may not only be related to, e.g., different body composition and impaired organ function due to underlying diseases as well as polypharmacy, but also to the reduced capability Figure 1 Epigenetic regulation of ADME gene expression by DNA methylation and DNA hydroxymethylation. Unmethylated DNA in gene promoters allows binding of transcription factors (TF) and coactivators (CoA) leading to active gene transcription. DNA methylation, i.e., the covalent addition of a CH 3 -group to 5
0 Cs of cytosines within CpG dinucleotides, of gene promoters is catalyzed by DNA methyltransferases (DNMT) and leads to suppression of gene expression. 5-methylcytosine (5-mC) underlies oxidative DNA demethylation catalyzed by members of the ten-eleven translocation (TET) enzyme family, resulting in hydroxymethylated DNA (5-hmC). Further intermediates of the DNA demethylation process include 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC). DNA methylation as well as DNA hydroxymethylation are dynamic and can be influenced by environmental or host factors (e.g., age, sex, disease state).
to metabolize and/or transport drugs. 16 Major research activities are warranted to fully comprehend the impact of DNA methylation on ADME gene expression and function related to these different subgroups.
In addition to interindividual variability of DNA methylation, marked intraindividual differences, particularly in DNA methylation patterns between various normal tissues and cell types, are observed. These differences may be even more pronounced between tumor and normal tissues. 5 DNA hydroxymethylation is a further recently identified covalent modification of DNA with an impact on gene expression. Instead of a methyl group, cytosines are substituted with a hydroxymethyl (CH 2 -OH) group at the 5 0 C (5-hmC). DNA hydroxymethylation is suggested to be an intermediate in the oxidative DNA demethylation pathway mediated by TET enzymes, 17 and is proposed to interact with transcriptional and chromatin modifiers as well. The effect of DNA hydroxymethylation on expression of the respective gene is not yet fully understood and is presumably context-dependent. DNA hydroxymethylation in gene bodies, i.e., in the gene region downstream of the first exon and upstream of the 3 0 UTR (untranslated region), has been shown to be associated with active transcription. However, 5-hmC in proximity to transcription start sites can either have a repressive or an activating effect. 17 The abundance of 5-hmC is tissue-specific, with high levels occurring, e.g., in brain, liver, and kidney. 18 In addition, DNA hydroxymethylation is dependent on developmental stage (fetus vs. adults) 19 and varies among individuals of different age, 20 thereby contributing significantly to interindividual variability of gene expression. An important aspect to be considered when looking at previous DNA methylation studies is that the majority of these are based on bisulfite treatment of genomic DNA, which has been accepted as the gold standard to examine DNA methylation profiles. However, methods based on bisulfite treatment cannot distinguish between methylated and hydroxymethylated DNA. Meanwhile, methods have been developed, e.g., TET-assisted bisulfite sequencing (TAB-seq) or oxidative bisulfite sequencing (OxBS-seq), 21 which are able to differentiate between 5-mC and 5-hmC, thereby allowing examination of the individual influence of DNA methylation or hydroxymethylation on gene expression. The specific influence of DNA hydroxymethylation on the regulation of ADME genes in adults has been addressed in a pilot study by Ivanov et al., investigating DNA methylation as well as hydroxymethylation in a set of 191 ADME genes using targeted TAB-seq in 20 human liver samples, demonstrating a correlation of the abundance of 5-mC and 5-hmC with interindividual variability in ADME gene expression (Abstract: 13 th European ISSX Meeting 2015; Ivanov, M. et al). However, large-scale studies that evaluate the role of hydroxymethylation for ADME genes have not yet been reported. Such studies will be essential to better delineate the impact of hydroxymethylation in normal as well as tumor tissues in terms of drug safety and effectiveness.
Finally, two further intermediates, 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC), are involved in the oxidative DNA demethylation process. Both 5-fC and 5-caC are considered unstable intermediates and their potential functional influence remains to be elucidated. 17 REGULATION OF ADME GENE EXPRESSION BY DNA METHYLATION As genetic variation in ADME genes cannot fully account for interindividual variability of drug response, current research aims to identify the epigenetic component of ADME gene regulation. A comprehensive summary of currently available knowledge regarding regulation of ADME gene expression by DNA methylation is given in Tables 1-3 , distinguishing between drugmetabolizing enzymes, drug transporters, and modifiers like nuclear receptors. The role of DNA methylation for selected genes is highlighted below.
Phase I and phase II enzymes
The hepatic expression of one of the major drug-metabolizing phase I enzymes, CYP3A4, is extremely variable among individuals (>100-fold), 22 but the contribution of genetic variants to this interindividual variability is rather low. Habano et al. 23 showed that DNA methylation of a CpG island in the 5 0 UTR about 25 kb distal of the CYP3A4 transcription start site does not affect gene expression. However, as demonstrated by Kacevska et al., 24 DNA methylation at CpG sites near or within binding sites for various transcription factors (e.g., C/EBP or HNF4a) in a 12 kb upstream promoter region has an influence on the expression of CYP3A4. DNA methylation at several CpG sites was shown to be highly variable and correlated with CYP3A4 expression in adult liver. The lack of CYP3A4 expression in fetal liver could be explained by DNA hypermethylation within the investigated region. In contrast, regions with important transcription factor binding sites were hypomethylated in adult liver where CYP3A4 is expressed. The expression of CYP1A1 has also been described to be influenced by DNA methylation. Hypermethylation of a CYP1A1 enhancer region has been shown to be associated with dioxin responsiveness in prostate cancer cell lines. 25 Furthermore, CYP1A1 methylation levels are influenced by smoking. A dose-dependent reduction of the CYP1A1 promoter DNA methylation from nonsmoker to heavy smokers was observed, suggesting a role of DNA methylation for the induction of CYP1A1 in human lung due to tobacco smoking. 26 Tekpli et al. 27 report that CYP1A1 enhancer methylation was associated both with mRNA expression and smoking-induced DNA adducts in normal human lung. Interestingly, only recently He et al. 28 reported an association of CYP1A1 hypermethylation with a higher susceptibility to antituberculosis drug-induced liver injury (ADLI) in a cohort of 127 tuberculosis patients developing ADLI and 127 tuberculosis patients without liver injury. The influence of DNA methylation on the expression of CYP1B1 has been shown in various cancer tissues. Overexpression of CYP1B1 has been related to decreased promoter and enhancer DNA methylation at ARNT and Sp1 transcription factor binding sites in prostate cancer. 29 Widschwendter et al. 30 found that CYP1B1 hypermethylation levels are associated with better survival in tamoxifen-treated breast cancer patients. Although CYP1B1 expression levels were not determined in that study, assuming that patients with higher methylation levels expressed less CYP1B1, these patients would be expected to retain higher levels of the active drug, consistent with the observed improved survival CpG island in the GPx3 promoter hypermethylated accompanied by decreased GPx3 mRNA expression in esophageal squamous cell carcinoma
GPx3 promoter methylation is associated with resistance to cisplatin treatment in patients with head and neck cancer rate. In a cohort of adolescent and young adult patients with acute lymphoblastic leukemia, hypermethylation and reduced CYP1B1 expression in peripheral blood cells was associated with worse overall survival. 31 In 1992, Jones et al. 32 found DNA methylation in the 5 0 flanking region of the CYP2E1 gene to be responsible for the lack of transcription in fetal liver, in contrast to adult liver, where CYP2E1 is expressed and not methylated. Vieira et al. 33 subsequently showed that demethylation of the 5 0 region during the neonatal period resulted in increased CYP2E1 mRNA expression. Interestingly, CYP2E1 overexpression due to DNA hypomethylation has been shown in patients with Parkinson's disease. 34 CYP2W1 is inherently expressed only in fetal colon, but not in normal adult tissue. Re-expression of CYP2W1 has been observed in colorectal cancer and has therefore been suggested as a prognostic marker for malignancy in colon cancer. 35 In addition, the cancer-specific expression can be exploited for the treatment of colon cancer with prodrugs bioactivated by CYP2W1 (e.g., duocarmycin) to selectively kill cancer cells. hypomethylation of the ABCB1 promoter is associated with ABCB1 expression and is associated with treatment resistance in a T-cell leukemia cell line; association of DNA methylation with expression also seen in chronic lymphocytic leukemia samples Interestingly, Gomez et al. 37 showed that DNA methylation in the CpG-rich first exon/intron junction was involved in the regulation of gene expression in colon tumor tissue. Only recently, developmental stage-specific CYP2W1 expression in human fetal colon was also found to be governed by methylation in this gene region. 38 Glutathione peroxidase 3 (GPx3) functions to protect cells from oxidative damage by catalyzing the reduction of reactive oxygen species (ROS). GPx3 promoter hypermethylation is a major contributor to suppressed GPx3 expression in multiple human cancer tissues, such as breast, prostate, renal, cervical, and gastric cancer or acute myeloid leukemia (see Table 1 ). According to a study by Chen et al., 39 GPx3 hypermethylation is tightly related with cisplatin resistance and poor survival in patients with head and neck cancer.
The enzyme UGT1A1, involved in phase II drug metabolism, catalyzes the inactivation of SN-38, the active metabolite of irinotecan, a drug used to treat metastatic colon cancer. UGT1A1 is variably expressed in colon cancer. In a study by Gagnon et al., 40 most colon cancer tissues showed only low UGT1A1 expression; however, some exhibited high expression levels. They could prove that in colon cancer cell lines UGT1A1 expression was tightly associated with promoter DNA methylation levels. From these results, the authors hypothesize that aberrant UGT1A1 expression, influenced by altered DNA methylation, contributes to differential sensitivity to irinotecan treatment. In a study by Oda et al., 41 methylation of the UGT1A1 promoter was identified to contribute to the lack of UGT1A1 expression in human kidney. The N-acetyltransferase 1 (NAT1), a phase II enzyme, is involved in the detoxification (N-acetylation) or bioactivation (O-acetylation) of arylamine carcinogens. NAT1 has been shown to be overexpressed in ER 1 breast cancer and to be associated with tamoxifen responsiveness. 42 According to Kim et al., 43 reduced promoter DNA methylation of NAT1 leads to the increased expression in breast cancer tissue. 44 In a subsequent study, they compared tamoxifenresistant and nonresistant breast cancer patients and suggested that higher NAT1 methylation was associated with nonresponse.
In addition to candidate gene studies, recently a genome-wide analysis has been performed on evaluating the biological significance of DNA methylation of DME genes on their mRNA expression in adult human liver tissues by combining these results with corresponding data from the Gene Expression Omnibus (GEO) database of the National Center for Biotechnology Information (NCBI). Of note, 37 DME genes revealed highly variable DNA methylation, of which DNA methylation was inversely correlated with mRNA expression for seven DME genes (CYP1A2, CYP2C19, CYP2D6, GSTA4, GSTM5, GSTT1, and SULT1A1). Moreover, the authors provide evidence that DNA methylation status around the first exon is responsible for tissuespecific (e.g., hepatic vs. intestinal tissue) and age-dependent expression of UGT1A isoforms by guiding correct alternative splicing of the UGT1A gene. 45 Very recently, the contribution of genetic variation and epigenetic factors to the regulation of gene expression including ADME genes in human liver was investigated by a genome-wide approach. Interestingly, a larger effect of methylation level at single CpG sites on hepatic expression was found for five ADME genes (GSTT1, GSTM1, UGT1A1, GST01, and PON1) whose expression levels are altered additionally by gene-specific variants. This study provides first evidence that a combination of genetic and epigenetic regulation by DNA methylation may better predict interindividual variability of gene expression than either of the two alone. 15 Interestingly, Petersen et al. 46 recently suggested that DNA methylation affects human metabolism. They performed an epigenome-wide association study (EWAS) between DNA methylation and metabolic traits in human blood and found significant associations also for CpG loci associated with the ADME genes UGT2B15 and ABCG1. However, in general the effects of DNA methylation on the metabolic traits were not as strong as the effects observed for genotypes. Direct monitoring of DNA methylation-based biomarkers in body fluids, such as plasma or serum, as currently suggested for cancer or disease biomarkers, would presumably allow better prediction and could facilitate clinical implementation. 47 
Transporters
Epigenetic regulation of transporter gene expression by DNA methylation has been shown for members of the ABC as well as the SLC transporter family ( Table 2) . It is well known that increased expression of the ABCB1 gene, encoding for the multidrug resistance protein MDR1 (P-glycoprotein), may lead to acquired cancer treatment resistance. Besides other mechanisms (e.g., transcriptional induction by transcription factors such as HIF1a 48 ), DNA methylation in the ABCB1 gene promoter contributes to MDR1 overexpression in vitro (cancer cell lines). In vivo the expression of MDR1 in cancer tissues of patients diagnosed with acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, colorectal cancer, and bladder cancer was linked to promoter DNA methylation. 49 In addition, hypomethylation of the ABCB1 promoter was associated with poor drug response and, together with hypomethylation of the GSTP1 promoter, related to inferior survival in vivo in breast cancer patients treated with doxorubicin. 50 For the breast cancer resistance protein (BCRP), mediating efflux of chemotherapeutic drugs, such as methotrexate, doxorubicin, or SN-38 (the active metabolite of irinotecan), drug resistance is linked to the DNA methylation status in the ABCG2 promoter, which results in overexpression of this transporter protein. As shown by Bram et al., 51 leukemic and ovarian cancer cell lines upregulated ABCG2 expression upon exposure to chemotherapeutic drugs accompanied by demethylation of the ABCG2 promoter, resulting in a significant increase in drug resistance compared to untreated cells. Aberrant drug uptake mediated by members of the SLC transporter family can also mediate drug resistance or toxicity. The SLC19A1 gene encodes for a carrier mediating the uptake of reduced folate and antifolate drugs such as methotrexate. Hypermethylation of the SLC19A1 promoter is associated with reduced expression in breast cancer cell lines 52 and has been associated with a lower response rate to methotrexate treatment in patients with CNS lymphomas. 53 Furthermore, members of the SLC22A gene family have been shown to be regulated by DNA methylation. The organic cation transporters (OCT) 1, 2, and 3, encoded by the genes SLC22A1, SLC22A2, and SLC22A3 respectively, mediate the uptake of several clinically relevant drugs including cancer agents (e.g., cisplatin or oxaliplatin). 54 OCT1 is primarily expressed in the liver, 55 but not in kidney, where the 5 0 UTR of the SLC22A1 gene is highly methylated compared to liver tissue (Figure 2) . 56, 57 In hepatocellular carcinoma, OCT1 Figure 2 Expression and DNA methylation of OCT1/SLC22A1, OCT2/SLC22A2 and OCT3/SLC22A3 in liver and kidney. Immunofluorescent staining of OCT1, OCT2, and OCT3 and DNA methylation profiles of the regulatory 5 0 UTR regions of SLC22A1, SLC22A2, and SLC22A3, investigated by MALDI-TOF mass spectrometry, in human liver (n 5 100) and kidney (n 5 18) tissue, respectively (see refs. 55, 57, 75, unpublished data). Median methylation levels at investigated CpG sites are represented by diamonds; 25%/75%-quantiles are depicted as shaded areas. OCT1 is expressed in human liver, but not in human kidney. Accordingly, DNA methylation in the 5 0 UTR of the SLC22A1 gene is low in liver (blue) and high in kidney tissues (yellow). In contrast, OCT2 is a kidney-specific transporter, showing low methylation levels in the 5 0 UTR of the SLC22A2 gene in kidney (yellow), but high methylation levels in liver (blue), where OCT2 is not expressed. OCT3 is expressed in liver as well as in kidney. The 5 0 UTR region of the SLC22A3 gene does not show differences in methylation profiles between the tissues. expression is downregulated due to DNA methylation, indicating impaired uptake and subsequent lower intracellular concentration of cancer agents, resulting in potential nonresponse. 57 Lin et al. 58 showed that long-term treatment with cisplatin leads to hypermethylation of the SLC22A1 gene and in consequence to cisplatin resistance in human esophageal cancer cells. The expression of OCT2 is kidney-specific. According to this tissue-specific expression, DNA methylation levels in the SLC22A2 promoter region is low in kidney tissue as compared to human liver missing OCT2 expression due to hypermethylation of SLC22A2 (Figure 2) . 56, 57 OCT3 is expressed in liver as well as in kidney and does not show different DNA methylation patterns in these organs (Figure 2) . However, aberrant DNA methylation of the SLC22A3 promoter has been identified as a regulatory factor in prostate cancer, corroborating the strong tissue-specific nature of epigenetic regulation. 59 The monocarboxylate transporter 4 (MCT4), encoded by the gene SLC16A3, is an important lactate transporter responsible for the extrusion of lactate in highly glycolytic cells, such as tumor cells. Independent from unspecific MCT4 inhibitors (e.g., statins), specific MCT4 inhibitors as promising cancer agents are currently under investigation. Interestingly, DNA methylation at a specific CpG site in the 5 0 regulatory region of the SLC16A3 promoter has been shown to correlate with expression of this lactate transporter and is strongly associated with survival of patients with clear cell renal cell carcinoma.
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Nuclear receptors
Nuclear receptors are a family of ligand binding transcription factors acting to induce expression of genes involved in various physiological processes in response to endogenous or exogenous stimuli, including the expression of ADME genes in response to xenobiotics. Nuclear receptors not only contribute to epigenetic regulation of gene expression by recruiting coactivators and corepressors mediating epigenetic modifications in target genes, but are also regulated epigenetically themselves. It can be assumed that aberrant expression of nuclear receptors due to changes in DNA methylation profiles results in aberrant activation of responsive ADME genes, and hence drug response. A major xenobiotic sensor and regulator of several ADME genes, including CYP3A4, UGT1A1 or ABCB1, is the pregnane X receptor (PXR/NR1I2). A comparison of PXR low-and PXR highexpression colon cancer cell lines showed that decreased expression of PXR is linked to promoter methylation in the NR1I2 gene and reduced transactivation of the CYP3A4 gene. In colorectal cancer tissues DNA methylation alters PXR expression as well, in that PXR expression is upregulated due to NR1I2 promoter hypomethylation. 23 Misawa et al. 62 found a link between NR1I2 DNA methylation in a CpG island in close proximity to exon3 and reduced NR1I2 gene expression in advanced neuroblastoma tumors, suggesting PXR to target genes with growth inhibitory functions. The effect of lower PXR levels due to hypermethylation on target gene expression like CYP3A4, however, was not analyzed in that study. Regarding the peroxisome proliferator-activated receptor g (PPARg), hypermethylation in colorectal cancer tissue is accompanied by reduced gene expression, advanced tumor stage, and poor patient survival. 63 Since
PPARg agonists are supposed to potentiate the efficacy for a number of chemotherapeutics, these authors hypothesize that a rational combination of chemotherapeutics with a PPARg agonist and an epigenetic drug reactivating PPARg expression in patients with silenced PPARg would sensitize tumors to anticancer treatment. The vitamin D receptor (VDR/NR1I1) plays an important role in mediating the response to calcitriol, which is the active metabolite of vitamin D. Calcitriol has been ascribed to mediate antiproliferative effects on tumor cells; however, cancer tissue and cell lines often show insensitivity to calcitriol treatment. 64 The expression of the VDR receptor is influenced by DNA methylation in colon and endometrial cancers. Interestingly, Marik et al. 64 show that combined treatment of breast cancer cell lines with the demethylating agent 5 0 aza-2 0 -deoxycytidine and calcitriol enhanced growth inhibitory effects accompanied by induction of VDR mRNA expression. Indeed, the NR1I1 promoter was hypermethylated in breast cancer cell lines as well as primary breast cancer tissue, resulting in reduced VDR expression and presumably to insensitivity to calcitriol treatment.
CONSEQUENCES FOR DRUG THERAPY
Whereas the contribution of DNA methylation on interindividual variability of expression of a number of ADME genes related to drug metabolism and transport has repeatedly been shown, the clinical relevance of DNA methylation to explain drug nonresponse and drug-induced toxicity needs further intensive evaluation. DNA methylation of specific ADME genes (e.g., GSTP1, GPx3, or SLC16A3) is currently proposed as biomarker for the diagnosis and prognosis of various cancers and has been associated with acquired drug resistance (Tables 1-3) . A major drawback of findings from in vitro studies with cultivated cancer cell lines generally used to investigate associations between ADME gene expression and DNA methylation is that extrapolation to the in vivo situation is limited, since expression and DNA methylation profiles do not necessarily resemble the profiles found in vivo. It is well known that gene expression and DNA methylation profiles of a number of genes involved in drug metabolism and transport are considerably different between cell lines and primary tissues. 65 Much less information is available with respect to the impact of DNA methylation in ADME genes and consequences for the treatment of diseases other than cancer. One explanation might be that investigations on DNA methylation are restricted methodologically by the availability of tissuespecific DNA, which is readily available from tumor biopsies or resection material, but rarely from nontumor tissue. Nevertheless, regarding psychiatric disorders, increased promoter DNA methylation of the serotonin transporter SLC6A4 in peripheral blood leukocytes has recently been associated with an increased risk for depression. 66 Interestingly, decreased promoter methylation levels in blood of depressed patients were associated with a lower response rate to antidepressant treatment using escitalopram. 67 In addition, DNA methylation of a CpG site in the ABCG1 gene was associated with fasting insulin levels and homeostasis model assessment of insulin resistance (HOMA-IR) in an EWAS with metabolically healthy volunteers. This indicates that DNA methylation at this CpG site might represent a marker for risk of metabolic disease or insulin resistance, with potential consequences for drug therapy. 68 However, a major limitation of these studies so far is the rather small sample size and limited phenotypic characterization of study populations.
The continuous development of high-throughput technologies to systematically analyze DNA methylation profiles on a genomewide level, i.e., EWAS, and their use in large-scale projects, such as the International Human Epigenome Consortium or the NIH Roadmap Epigenomics Mapping Consortium, will enable a more comprehensive understanding of the epigenetic component of ADME gene regulation, and will provide additional information for personalized drug treatment in the future. Moreover, the advancement of technologies to reliably and efficiently quantify 5-mC specifically in selected ADME genes, such as the method recently developed by Ivanov et al., 69 which uses next generation sequencing of bisulfite-converted DNA specifically enriched for coding and regulatory regions of 174 ADME genes, will also facilitate high-throughput analysis of DNA methylation with respect to drug response.
Most important, the function and relevance of DNA hydroxymethylation needs to be further evaluated to elucidate its role within the epigenetic machinery. Thus, the consideration of novel high-throughput technologies for quantification of not only 5-mC but also 5-hmc and further intermediates (5-fC and 5-caC) opens a new avenue in the understanding of epigenetic control of ADME genes.
The dynamic nature of DNA methylation, being influenced, e.g., by age, sex, environmental, and lifestyle factors, represents a major challenge for the integration of the knowledge into clinical practice. In contrast to genetic variations, DNA methylation, as epigenetic modification, is dynamic and reversible. Use of DNA methylation profiles as contributors to interindividual variability of drug response would require repeated investigation of biomarker gene DNA methylation profiles depending on patient age, treated target organ, or during long-term treatment. Moreover, not only interindividual variability of DNA methylation of ADME genes, but also of drug target genes may account for altered response to drug treatment. For instance, hypermethylation of the promoter of the epidermal growth factor receptor (EGFR) gene, for example, is associated with resistance to the EGFR-tyrosine kinase inhibitor gefitinib in nonsmall-cell lung cancer cells. 70 The concept of systems pharmacology 1 and the integration of epigenomic information not only on ADME genes but also other pharmacogenes will provide promising progress to better understand drug resistance and nonresponse.
On the other hand, the plasticity of DNA methylation provides an attractive opportunity for therapeutic intervention with so-called epidrugs. DNMT inhibitors, such as the nucleoside analogs 5-azacytidine and 5-aza-2 0 -deoxycytidine, are approved by the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome and for elderly patients with acute myeloid leukemia. Just as shown for tumor suppressor genes, ADME-related gene expression could be increased by drugs inhibiting DNA methylation. However, treatment with DNMT inhibitors is unspecific and causes genome-wide DNA demethylation, with potentially serious side effects (Figure 3) . Furthermore, both 5-azacytidine and 5-aza-2 0 -deoxycytidine rely on transportermediated uptake into the cells to be incorporated into the DNA, via, e.g., the human concentrative nucleoside transporter 1 (hCNT1). 71 Advancements in technologies to epigenetically edit selected target DNA sequences holds much promise to overcome the problem of global off-target effects. Different targeted approaches to epigenetically modify expression of specific genes have been established as powerful tools in biological research. The rationale of these approaches is to fuse a catalytically active effector domain, e.g., DNA methylating (DNMTs) or demethylating (TETs) enzymes, to a DNA-binding domain selectively targeting the effector to the target gene sequence. The currently most commonly applied tools differ in the way of mediating target sequence recognition, which can be achieved via protein/DNAbased interaction (zinc finger proteins or transcription activator like effectors [TALEs]) or RNA/DNA-based interaction (clustered regularly interspaced short palindromic repeats/CRISPRassociated 9 system [CRISPR/Cas9 system]) (Figure 3) . Zinc finger-DNA binding domains coupled to nucleases have already Targeted epigenetic editing at ADME gene promoters can be achieved by use of zinc finger proteins, TALEs, or the CRISPR/Cas9 system, specifically targeting DNA sequences of genes of interest, coupled to effector proteins, i.e., DNMTs or TETs.
